Last updated: June 26, 2026
Endometrial (uterine) cancer is among the most common gynecologic cancers, and its treatment landscape has shifted rapidly with recent immunotherapy approvals. This guide explains conventional standard-of-care, newer therapies, survival data, and how evidence-based integrative care can complement oncology treatment. At EuroMed Foundation in Arizona, the focus is on patient-centered, collaborative care that supports women through every stage of treatment.
What Is Endometrial Cancer and How Common Is It?
Endometrial cancer is a malignancy that begins in the lining (endometrium) of the uterus and is the most common gynecologic cancer in the United States. According to the NCI SEER Program, uterine cancer incidence is approximately 29 per 100,000 women, with a 2024 age-adjusted death rate of 5.47 per 100,000 women.
Incidence has been rising steadily. The CDC MMWR reported that uterine cancer incidence increased approximately 0.7% per year from 1999 to 2015, while mortality rose about 1.1% per year from 1999 to 2016. These trends help explain the growing demand for accurate, up-to-date treatment information.
How Is Endometrial Cancer Staged and Why Does Stage Matter?
Endometrial cancer is staged based on how far the disease has spread, generally categorized as localized (confined to the uterus), regional (spread to nearby lymph nodes or tissue), and distant (spread to distant organs). Stage directly determines treatment intensity and prognosis, guiding whether surgery alone or combined systemic therapy is recommended.
Localized disease often responds well to surgery, while regional and distant disease typically require multimodal treatment that may include radiation, chemotherapy, hormone therapy, or immunotherapy. Accurate staging is the foundation for an individualized treatment plan.
What Are dMMR/MSI-H and pMMR/MSS, and Why Do They Matter for Treatment?
dMMR (mismatch repair deficient) and MSI-H (microsatellite instability-high) describe tumors with defective DNA repair, while pMMR (mismatch repair proficient) and MSS (microsatellite stable) describe tumors with intact repair systems. These biomarkers are central to personalized treatment because dMMR/MSI-H tumors tend to respond particularly well to immunotherapy with PD-1 inhibitors.
Approximately 25-30% of endometrial cancers are dMMR, a widely cited literature range. Biomarker testing now routinely guides systemic therapy decisions, helping oncologists determine who is most likely to benefit from immune checkpoint inhibitors versus other systemic approaches.
What Are the Main Treatment Options for Endometrial Cancer?
The main treatment options for endometrial cancer are surgery, radiation, chemotherapy, hormone therapy, targeted therapy, and immunotherapy. The recommended approach depends on cancer stage, tumor grade, and biomarker status. For most patients, surgery is the foundation, with additional systemic or radiation therapy added based on the risk of recurrence and disease spread.
These pillars are often combined. Early-stage disease may be managed with surgery alone, while advanced or recurrent disease increasingly involves chemotherapy paired with immunotherapy. The sections below explain when each modality is used.
When Is Surgery (Hysterectomy) the Recommended Treatment?
Surgery, specifically a hysterectomy, is the gold-standard treatment for most endometrial cancers and is typically the first step for localized disease. A hysterectomy removes the uterus and is often combined with removal of the ovaries, fallopian tubes, and nearby lymph nodes to confirm staging and reduce recurrence risk.
The field has shifted toward minimally invasive and robotic surgery. Temporal trends analyses show increased use of robotic procedures and decreased laparotomy, contributing to improved 30-day and 90-day mortality outcomes and faster recovery compared with traditional open surgery.
When Are Radiation and Chemotherapy Used?
Radiation and chemotherapy are used based on stage and recurrence risk. Radiation may be recommended after surgery to reduce local recurrence, while chemotherapy – most commonly carboplatin plus paclitaxel – treats higher-risk, advanced, or recurrent disease. For stage I-II disease, the choice among radiation, chemotherapy, and hormone therapy depends on individual risk factors.
For many patients with early-stage, low-risk disease, surgery alone is sufficient. Higher-grade tumors or those with deeper invasion may warrant adjuvant radiation or chemotherapy. Decisions are best made collaboratively with a gynecologic oncologist who weighs tumor characteristics against treatment side effects.
What Role Does Hormone Therapy Play?
Hormone therapy plays a key role for select patients, particularly those with low-grade, hormone-receptor-positive tumors or those unable to undergo surgery. Progestin-based therapies and other hormonal agents can slow or shrink tumor growth and form the basis of many fertility-sparing approaches for early-stage disease.
Hormone therapy is often considered for patients seeking uterus preservation or for advanced disease where systemic control is needed with fewer toxicities than chemotherapy. This approach leads directly into fertility-sparing strategies discussed later.
How Is Immunotherapy Changing Advanced Endometrial Cancer Treatment?
Immunotherapy is transforming advanced endometrial cancer treatment, with PD-1 inhibitors combined with chemotherapy now becoming front-line standard of care for both dMMR and pMMR primary advanced or recurrent disease. Following major FDA approvals in mid-2024 and supported by phase III trials such as RUBY, these regimens have demonstrated significant survival improvements over chemotherapy alone.
This shift reflects a broader move toward biomarker-driven, personalized oncology. Patients with dMMR/MSI-H tumors often see the most dramatic benefit, but immunotherapy combinations are now extending benefit across biomarker groups.
What Is Dostarlimab (Jemperli) and What Did the RUBY Trial Show?
Dostarlimab (Jemperli) is a PD-1 inhibitor that, in combination with carboplatin and paclitaxel, received expanded FDA approval in August 2024 for primary advanced or recurrent endometrial cancer. The phase III RUBY trial demonstrated meaningful survival improvements, establishing this combination as a key treatment advance.
The table below summarizes key RUBY trial outcomes reported by the U.S. FDA and published in the New England Journal of Medicine.
| Outcome | Dostarlimab + Chemo | Placebo + Chemo |
|---|---|---|
| Median overall survival (overall population) | 44.6 months | 28.2 months |
| Median progression-free survival | 11.8 months | 7.9 months |
| dMMR/MSI-H risk of death reduction | 68% (HR 0.32; 95% CI 0.17-0.63; p=0.0002) | |
The overall population overall survival benefit reached statistical significance (HR 0.69; 95% CI 0.54-0.89; p=0.002), while the dMMR/MSI-H subgroup showed the most pronounced reduction in death risk.
What Is Durvalumab (Imfinzi) and Who Is It For?
Durvalumab (Imfinzi) is a PD-L1 inhibitor approved by the FDA in June 2024 in combination with carboplatin and paclitaxel for adults with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This approval, supported by the DUO-E trial, expanded immunotherapy options for biomarker-selected patients.
According to the U.S. FDA, durvalumab is specifically indicated for the dMMR population. The DUO-E trial also evaluated the addition of olaparib, reflecting ongoing efforts to refine combination strategies for advanced disease.
Who Is Eligible for Immunotherapy for Endometrial Cancer?
Eligibility for immunotherapy in endometrial cancer is determined primarily by disease stage and biomarker status. Current FDA approvals focus on patients with primary advanced or recurrent disease. Dostarlimab plus chemotherapy is approved across biomarker groups, while durvalumab plus chemotherapy is specifically approved for dMMR tumors.
Biomarker testing for mismatch repair and MSI status is essential to determine candidacy. Patients should discuss tumor testing results with their oncology team to understand which immunotherapy regimens are appropriate for their specific diagnosis.
What Emerging Therapies and Clinical Trials Should Patients Know About?
Emerging therapies for endometrial cancer include antibody-drug conjugates (ADCs) and additional targeted agents under active investigation. Trastuzumab deruxtecan (T-DXd) has been approved in specific HER2-positive recurrent settings, and phase III trials of TROP2-directed ADCs are ongoing for recurrent disease.
Clinical trials remain an important option, particularly for recurrent or treatment-resistant disease. Patients interested in trial enrollment should ask their oncology team about eligibility criteria, biomarker requirements, and trials evaluating immunotherapy combinations, ADCs, and other novel agents.
What Are the Survival Rates and Prognosis for Endometrial Cancer?
Endometrial cancer has a favorable overall prognosis, with a 5-year relative survival of 80.9% according to SEER 2016-2022 data. Survival varies significantly by stage: 94.9% for localized disease, 70.1% for regional disease, and 19.9% for distant disease, underscoring the importance of early detection.
The table below presents stage-specific survival from the NCI SEER Program.
| Stage | 5-Year Relative Survival |
|---|---|
| Localized | 94.9% |
| Regional | 70.1% |
| Distant | 19.9% |
| All stages combined | 80.9% |
Outcomes have improved over time as treatment techniques have evolved. Temporal trends data show that increased use of minimally invasive surgery and immunotherapy has contributed to better short-term mortality and overall survival, particularly for early-stage disease.
What Are the Side Effects of Endometrial Cancer Treatment and How Can They Be Managed?
Side effects of endometrial cancer treatment vary by modality. Chemotherapy with carboplatin and paclitaxel can cause fatigue, nausea, hair loss, neuropathy, and low blood counts. Immunotherapy can trigger immune-related adverse events, and surgery requires a recovery period. Coordinated supportive care helps patients manage these effects throughout treatment.
Effective symptom management combines conventional supportive care with evidence-based integrative approaches. Proactive monitoring, communication with the oncology team, and individualized care planning are central to maintaining quality of life during treatment.
How Long Does Recovery Take After a Hysterectomy?
Recovery after a hysterectomy depends on the surgical approach. Minimally invasive or robotic hysterectomy typically allows return to most activities within two to four weeks, while open (abdominal) surgery may require six to eight weeks. Full internal healing continues beyond the initial recovery period.
The trend toward robotic and laparoscopic techniques has shortened recovery times and reduced complications compared with traditional open surgery. Patients should follow their surgical team’s specific guidance on activity, lifting restrictions, and follow-up care.
What Are Immune-Related Side Effects and Why Must They Be Monitored?
Immune-related adverse events (irAEs) are side effects unique to immunotherapy that occur when the immune system attacks healthy tissue, potentially affecting the skin, thyroid, lungs, liver, or colon. These effects require careful monitoring and prompt management, as outlined in the ASCO irAE management guideline.
Coordination with the oncology team is essential. Richard T. Lee, MD, Medical Director of Integrative Oncology at City of Hope Comprehensive Cancer Center and co-author of the SIO-ASCO Joint Integrative Oncology Guidelines, underscores that supportive integrative interventions for patients on immune checkpoint inhibitors must be coordinated with the oncology team and with careful monitoring for immune-related adverse events.
Are There Fertility-Sparing and Uterus-Preserving Treatment Options?
Fertility-sparing and uterus-preserving options are available for carefully selected patients with early-stage, low-grade endometrial cancer who wish to preserve the uterus. These approaches typically use hormonal therapy, such as high-dose progestins or a levonorgestrel intrauterine system, instead of immediate hysterectomy, under close oncologic monitoring.
These options require careful patient selection and ongoing surveillance, including periodic biopsies to confirm response. Definitive surgery is generally recommended after childbearing or if the cancer does not respond. Patients considering alternative and uterine cancer treatment approaches should discuss the risks and benefits with a gynecologic oncologist.
How Does Integrative and Holistic Care Support Endometrial Cancer Treatment?
Integrative and holistic care supports endometrial cancer treatment by addressing symptom management, quality of life, and overall well-being alongside conventional oncology. Evidence-based integrative therapies are intended to complement – not replace – standard treatment, helping patients manage side effects and maintain function throughout their care journey.
As Debu Tripathy, MD, Professor and Medical Oncologist at The University of Texas MD Anderson Cancer Center and co-author of the SIO-ASCO Joint Guidelines, emphasizes, evidence-based integrative therapies are intended for symptom management during cancer treatment and to complement – not replace – conventional oncology care.
Can Diet, Exercise, and Weight Management Help During and After Treatment?
Diet, exercise, and weight management can play a supportive role during and after endometrial cancer treatment. Because obesity is a known risk factor for endometrial cancer, maintaining a healthy weight, staying physically active, and following a balanced diet may support recovery, improve energy, and contribute to long-term survivorship health.
These lifestyle measures are increasingly recognized as part of comprehensive survivorship care. While not a substitute for medical treatment, they can help address cardiometabolic health and overall well-being, particularly important given the metabolic factors associated with this cancer.
What Evidence-Based Integrative Therapies Help With Symptoms and Side Effects?
Evidence-based integrative therapies that may help with cancer-related symptoms include approaches supported by the SIO-ASCO Joint Guidelines for managing issues such as anxiety, fatigue, nausea, and pain during treatment. These interventions are intended to support symptom relief and quality of life when coordinated with the oncology team.
- Mind-body practices for anxiety and stress management
- Movement-based therapies to support energy and physical function
- Nutritional guidance to support overall health
- Supportive techniques for nausea and treatment-related discomfort
All integrative interventions should be discussed with the treating oncologist, especially for patients receiving immunotherapy, to ensure safety and avoid interactions.
Why Is a Personalized, Multidisciplinary Treatment Plan Important?
A personalized, multidisciplinary treatment plan is important because endometrial cancer treatment depends on stage, tumor biology, biomarker status, and individual patient goals. Coordinated care that brings together surgical, medical, and integrative oncology expertise helps ensure that treatment is both evidence-based and aligned with each patient’s values and circumstances.
Research consistently shows that patients desire individualized, collaborative care. This model, central to the approach at EuroMed Foundation in Arizona, connects conventional oncology with supportive integrative services to address the full scope of a patient’s needs.
How Should Patients Choose a Treatment Approach and Care Team?
Patients should choose a treatment approach and care team by prioritizing biomarker testing, seeking clear communication, and ensuring access to multidisciplinary expertise. Understanding tumor stage and biomarker status (dMMR/MSI-H versus pMMR/MSS) is essential, as these factors directly determine eligibility for immunotherapy and other personalized treatments.
Helpful questions to ask an oncology team include:
- What is my cancer stage, grade, and biomarker status?
- Which treatment options are recommended, and why?
- Am I a candidate for immunotherapy or a clinical trial?
- What side effects should I expect, and how will they be managed?
- How can integrative or supportive care be coordinated with my treatment?
Choosing a care team that values collaboration and individualized planning helps patients make informed decisions throughout their treatment journey.
Frequently Asked Questions About Endometrial Cancer Treatment
The following concise answers address common questions about endometrial cancer treatment, drawn from current evidence and FDA-approved treatment standards.
What Is the Best Treatment for Endometrial Cancer?
The best treatment for endometrial cancer depends on stage and biomarker status. Surgery (hysterectomy) is the foundation for most cases, with radiation, chemotherapy, hormone therapy, or immunotherapy added as indicated. Treatment is individualized based on tumor characteristics and patient goals.
Can Endometrial Cancer Be Cured?
Endometrial cancer is often curable when detected early. According to SEER 2016-2022 data, localized disease has a 5-year relative survival of 94.9%. Outcomes decline with more advanced stages, which is why early diagnosis and prompt treatment are critical.
Is Immunotherapy Available for All Stages of Endometrial Cancer?
No. Current FDA approvals for immunotherapy focus on primary advanced or recurrent endometrial cancer, not all stages. Eligibility is tied to biomarker status, with dostarlimab approved across biomarker groups and durvalumab approved specifically for dMMR disease.
Are Holistic Treatments a Replacement for Conventional Cancer Treatment?
No. Evidence-based integrative and holistic therapies are intended to complement, not replace, conventional cancer treatment. Per SIO-ASCO guidance, these approaches support symptom management and quality of life and should always be coordinated with the oncology team.
What Are the Key Takeaways for Endometrial Cancer Treatment in 2026?
Endometrial cancer treatment in 2026 centers on surgery, radiation, chemotherapy, hormone therapy, and a rapidly expanding role for immunotherapy. The mid-2024 FDA approvals of dostarlimab and durvalumab have made PD-1/PD-L1 inhibitor combinations a new standard for advanced and recurrent disease, while early-stage outcomes remain strong.
Biomarker testing, individualized planning, and evidence-based integrative care together support better outcomes and quality of life. Early-stage disease carries excellent survival rates, and supportive therapies can help patients manage treatment side effects when coordinated with their oncology team.
If you or a loved one is navigating an endometrial cancer diagnosis, EuroMed Foundation in Arizona offers patient-centered, collaborative care that integrates evidence-based supportive therapies with conventional oncology. Reach out to learn how a multidisciplinary team can support your treatment journey.
Frequently Asked Questions
What is the best treatment for endometrial cancer?
The best treatment for endometrial cancer depends on the cancer’s stage and biomarker status. Surgery, specifically a hysterectomy, is the foundation for most cases, with radiation, chemotherapy, hormone therapy, or immunotherapy added as indicated. For advanced or recurrent disease, PD-1 inhibitors combined with chemotherapy are now front-line standard of care. Treatment is always individualized based on tumor characteristics and patient goals.
What are the survival rates for endometrial cancer by stage?
Endometrial cancer has a 5-year relative survival of 80.9% across all stages, according to SEER 2016-2022 data. Survival varies significantly by stage: 94.9% for localized disease confined to the uterus, 70.1% for regional disease that has spread to nearby tissue, and 19.9% for distant disease. These figures highlight the importance of early detection for a favorable prognosis.
How long does recovery take after a hysterectomy for endometrial cancer?
Recovery after a hysterectomy depends on the surgical approach used. Minimally invasive or robotic hysterectomy typically allows return to most activities within two to four weeks, while open abdominal surgery may require six to eight weeks. Full internal healing continues beyond this initial recovery period. The growing use of robotic and laparoscopic techniques has shortened recovery times and reduced complications compared with traditional open surgery.
Who is eligible for immunotherapy for endometrial cancer?
Eligibility for immunotherapy is determined by disease stage and biomarker status. Current FDA approvals focus on patients with primary advanced or recurrent disease, not all stages. Dostarlimab plus chemotherapy is approved across biomarker groups, while durvalumab plus chemotherapy is approved specifically for mismatch repair deficient (dMMR) tumors. Biomarker testing for mismatch repair and MSI status is essential to determine candidacy.
What did the RUBY trial show about dostarlimab for endometrial cancer?
The phase III RUBY trial showed that dostarlimab (Jemperli) plus carboplatin and paclitaxel significantly improved survival in advanced or recurrent endometrial cancer. Median overall survival reached 44.6 months versus 28.2 months with chemotherapy alone, and median progression-free survival was 11.8 versus 7.9 months. The dMMR/MSI-H subgroup saw a 68% reduction in the risk of death. The FDA expanded its approval in August 2024.
Are there fertility-sparing treatment options for endometrial cancer?
Yes, fertility-sparing and uterus-preserving options are available for carefully selected patients with early-stage, low-grade endometrial cancer. These approaches typically use hormonal therapy, such as high-dose progestins or a levonorgestrel intrauterine system, instead of immediate hysterectomy. They require close oncologic monitoring, including periodic biopsies to confirm response. Definitive surgery is generally recommended after childbearing or if the cancer does not respond.
Can holistic treatments replace conventional endometrial cancer treatment?
No, evidence-based integrative and holistic therapies are intended to complement, not replace, conventional cancer treatment. Per SIO-ASCO guidance, these approaches support symptom management and quality of life for issues such as anxiety, fatigue, nausea, and pain. All integrative interventions should be coordinated with the oncology team, especially for patients receiving immunotherapy, to ensure safety and avoid interactions.